Dong‐Sheng Zhang
机构：Sun Yat-sen University, Shandong Provincial Hospital, Sun Yat-sen University Cancer Center, Shandong First Medical University · ORCID：0000-0002-8884-4181
发表论文 24 篇 · 总被引 356 次 · h-index 6
代表论文
- Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial (2024 · Nature Medicine · 被引 177)
- Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial (2025 · The Lancet Oncology · 被引 63)
- A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study) (2022 · Clinical Cancer Research · 被引 60)
- A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer (2022 · 癌症：英文版 · 被引 25)
- A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer. (2023 · Journal of Clinical Oncology · 被引 22)
- Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis (2024 · npj Precision Oncology · 被引 7)